Compositions and methods for determining the presence of SARS coronavirus in a sample
First Claim
Patent Images
1. A detection probe for use determining the presence of SARS-CoV in a test sample, said probe being up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within the sequence of SEQ ID NO:
- 1 or its complement under stringent hybridization conditions, wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to oligonucleotides useful for determining the presence of SARS coronavirus in a test sample. The oligonucleotides of the present invention may be incorporated into detection probes, capture probes and amplification oligonucleotides, or used in various combinations thereof.
11 Citations
115 Claims
-
1. A detection probe for use determining the presence of SARS-CoV in a test sample, said probe being up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within the sequence of SEQ ID NO:
- 1 or its complement under stringent hybridization conditions, wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
15. A detection probe for use determining the presence of SARS-CoV in a test sample, said probe being up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within the sequence of SEQ ID NO:
- 3 or its complement under stringent hybridization conditions, wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions.
- View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
- 38. An oligonucleotide set comprising two or more oligonucleotides capable of amplifying a target region of nucleic acid derived from SARS-CoV under amplification conditions, said target region being contained within the sequence of SEQ ID NO:
- 68. An oligonucleotide set comprising two or more oligonucleotides capable of amplifying a target region of nucleic acid derived from SARS-CoV under amplification conditions, said target region being contained within the sequence of SEQ ID NO:
-
99. A method for determining the presence of SARS-CoV in a test sample, said method comprising the steps of:
-
a) contacting a test sample a detection probe up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within a SARS-CoV 5′
leader sequence or its complement, wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions; and
b) determining whether said hybrid is present in said test sample as an indication of the presence of SARS-CoV in said test sample. - View Dependent Claims (100, 101, 102, 103, 104, 105)
-
-
106. A method for amplifying a target region of nucleic acid derived from SARS-CoV, said method comprising the steps of:
-
a) contacting a test sample with one or more amplification oligonucleotides under amplification conditions, wherein a first of said amplification oligonucleotides comprises a target binding portion which binds to a target region fully contained within a SARS-CoV 5′
leader sequence or its complement under said conditions, wherein said first amplification oligonucleotide does not contain any other base sequences which stably hybridize to nucleic acid derived from SARS-CoV under said amplification conditions; and
b) exposing said test sample to said conditions such that said target region, if present in said test sample, is amplified. - View Dependent Claims (107, 108, 109, 110)
-
-
111. A method for determining the presence of SARS-CoV in a test sample, said method comprising the steps of:
-
a) contacting a test sample with a detection probe up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within a SARS-CoV 3′
co-terminal sequence or its complement, wherein said probe forms a hybrid stable for detection with said target sequence under stringent hybridization conditions, and wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions; and
b) determining whether said hybrid is present in said test sample as an indication of the presence of SARS-CoV in said test sample. - View Dependent Claims (112, 113)
-
-
114. A method for amplifying a target region of nucleic acid derived from SARS-CoV, said method comprising the steps of:
-
a) contacting a test sample with one or more amplification oligonucleotides under amplification conditions, wherein a first of said amplification oligonucleotides comprises a target binding portion which binds to a target region contained within a SARS-CoV 3′
co-terminal sequence or its complement under said conditions; and
b) exposing said test sample to said conditions such that said target region, if present in said test sample, is amplified. - View Dependent Claims (115)
-
Specification